Difference between revisions of "Lung Density Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
Line 68: Line 68:
 
*[[Media:FDA-COPDGuidance-20100201.pdf|FDA Guidance for Industry - Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment]]
 
*[[Media:FDA-COPDGuidance-20100201.pdf|FDA Guidance for Industry - Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment]]
  
−
*[[Media:QIBA COPD Asthma as of 8-24-12.pdf|QIBA COPD/Asthma Technical Committee Roster]]
+
*[[Media:QIBA COPD Asthma Roster.pdf|QIBA COPD/Asthma Technical Committee Roster]]
  
 
==Round 2 of QIBA Funded Projects==
 
==Round 2 of QIBA Funded Projects==
 
*[[University of Wisconsin]]
 
*[[University of Wisconsin]]

Revision as of 17:12, 18 September 2012

This Wiki is for collaborative creation of QIBA's Chronic Obstructive Pulmonary Disease (COPD) and Asthma Committee materials and ongoing activities.


Mission: Reduce and characterize bias and variance across manufacturers, versions, and sites in support of quantitative CT lung densitometry and morphology.

Initial Objectives:

  • Characterize the precision and accuracy of phenotyping and progression measurements in emphysema and asthma.
This is an essential effort to classify phenotype and assess longitudinal changes as medically meaningful surrogates for health status.
  • Compare the sensitivity of CT measurements to spirometry and other accepted measures.
This will be necessary in order to determine if Progressive Disease can be detected significantly sooner with quantitative imaging techniques than with currently accepted methods.


Profiling Activities

Protocol Development Activities

Groundwork Activities

Validate key concepts and answer key questions needed to write the Profiles and demonstrate their effectiveness.

  • Phantom project

Meetings / Call Summaries


Working Documents


Reference Documents

Round 2 of QIBA Funded Projects

Retrieved from "https://qibawiki.rsna.org/index.php?title=Lung_Density_Biomarker_Ctte&oldid=5429"